BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21844569)

  • 41. Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.
    Tot T
    Ann Surg Oncol; 2015 Aug; 22(8):2532-9. PubMed ID: 25582746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
    Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
    Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
    Idvall I; Andersson C; Fallenius G; Ingvar C; Ringberg A; Strand C; Akerman M; Fernö M
    Acta Oncol; 2001; 40(5):653-9. PubMed ID: 11669340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
    Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
    J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
    Park SS; Kim JE; Kim YA; Kim YC; Kim SW
    Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
    Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
    Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histopathological grading of breast ductal carcinoma in situ: validation of a web-based survey through intra-observer reproducibility analysis.
    Schuh F; Biazús JV; Resetkova E; Benfica CZ; Ventura Ade F; Uchoa D; Graudenz M; Edelweiss MI
    Diagn Pathol; 2015 Jul; 10():93. PubMed ID: 26159429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.
    Monabati A; Sokouti AR; Noori SN; Safaei A; Talei AR; Omidvari S; Azarpira N
    Int J Clin Exp Pathol; 2015; 8(4):3963-70. PubMed ID: 26097582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variability in grading of ductal carcinoma in situ among an international group of pathologists.
    van Seijen M; Jóźwiak K; Pinder SE; Hall A; Krishnamurthy S; Thomas JS; Collins LC; Bijron J; Bart J; Cohen D; Ng W; Bouybayoune I; Stobart H; Hudecek J; Schaapveld M; Thompson A; Lips EH; Wesseling J;
    J Pathol Clin Res; 2021 May; 7(3):233-242. PubMed ID: 33620141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
    Schorr MC; Pedrini JL; Savaris RF; Zettler CG
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
    Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
    Kalogeraki A; Garbagnati F; Santinami M; Zoras O
    In Vivo; 2002; 16(2):141-4. PubMed ID: 12073773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.